Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $71.09, for a total transaction of $71,090.00. Following the sale, the director now directly owns 84,394 shares of the company’s stock, valued at approximately $5,999,569.46. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Tuesday, October 17th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $71.10, for a total transaction of $284,400.00.
  • On Wednesday, September 13th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $65.47, for a total transaction of $65,470.00.
  • On Thursday, September 14th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $65.59, for a total transaction of $262,360.00.
  • On Wednesday, August 23rd, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.85, for a total transaction of $227,400.00.
  • On Thursday, July 20th, Lewis Clayton Jr. Cantley sold 9,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.36, for a total transaction of $507,240.00.

Agios Pharmaceuticals, Inc. (NASDAQ AGIO) traded down 1.56% during mid-day trading on Wednesday, reaching $69.59. 233,119 shares of the company traded hands. Agios Pharmaceuticals, Inc. has a 12-month low of $39.24 and a 12-month high of $72.73. The stock’s market capitalization is $3.37 billion. The company’s 50-day moving average is $66.25 and its 200-day moving average is $56.71.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.21). The firm had revenue of $11.30 million during the quarter, compared to analysts’ expectations of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. Agios Pharmaceuticals’s revenue for the quarter was up 62.1% on a year-over-year basis. During the same period in the previous year, the company earned ($1.47) earnings per share. Equities analysts predict that Agios Pharmaceuticals, Inc. will post ($7.08) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Agios Pharmaceuticals, Inc. (AGIO) Director Lewis Clayton Jr. Cantley Sells 1,000 Shares” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/18/agios-pharmaceuticals-inc-agio-director-lewis-clayton-jr-cantley-sells-1000-shares.html.

A number of hedge funds have recently modified their holdings of AGIO. BlackRock Inc. grew its stake in Agios Pharmaceuticals by 8,463.5% in the first quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after purchasing an additional 2,141,768 shares during the period. FMR LLC grew its stake in shares of Agios Pharmaceuticals by 14.1% in the second quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after acquiring an additional 895,584 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Agios Pharmaceuticals by 23.8% in the second quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after acquiring an additional 617,379 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Agios Pharmaceuticals by 748.0% in the first quarter. Goldman Sachs Group Inc. now owns 649,124 shares of the biopharmaceutical company’s stock worth $37,909,000 after acquiring an additional 572,579 shares during the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of Agios Pharmaceuticals in the second quarter worth $20,423,000. 93.97% of the stock is currently owned by institutional investors.

Several analysts have recently commented on the stock. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $76.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Royal Bank Of Canada assumed coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price objective for the company. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $83.00 price objective (up previously from $75.00) on shares of Agios Pharmaceuticals in a research report on Thursday, August 10th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Agios Pharmaceuticals has an average rating of “Buy” and an average price target of $75.20.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.